Fri, July 15, 2022

Derik De Bruin Downgraded (TXG) to Sell and Decreased Target to $35 on, Jul 15th, 2022

Derik De Bruin of B of A Securities, Downgraded "10x Genomics, Inc." (TXG) to Sell and Decreased Target from $80 to $35 on, Jul 15th, 2022.

Derik has made no other calls on TXG in the last 4 months.



There are 3 other peers that have a rating on TXG. Out of the 3 peers that are also analyzing TXG, 1 agrees with Derik's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $60 on, Thursday, July 14th, 2022


These are the ratings of the 2 analyists that currently disagree with Derik


  • Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $100 on, Friday, May 6th, 2022
  • Patrick Donnelly of "Citigroup" Maintained at Strong Buy with Decreased Target to $100 on, Thursday, May 5th, 2022